Angus Russell, chief executive of the speciality pharmaceutical firm Shire, has taken advantage of a strong performance from the group recently to sell a big chunk of shares.
He offloaded 17,219 at 1,029p each, or a total of about £177,000.
Following the sale Russell now has 96,331 shares in the group as well as various options and other rights.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Shares in Shire have rallied strongly in the past couple of months.
The company received a boost on Tuesday when it said data from the final two Phase III trials for its Gaucher disease treatment velaglucerase alfa met expectations.
Top Director Buys
Value: £75,200
Value: $68,000
Value: £44,183
Value: £15,610
Top Director Sells
Value: £952,400
Value: £524,097
Value: £191,350
Value: £177,184
Value: £13,022
-
Best-performing funds and investment trusts in stocks and shares ISAs of all timeAs ISAs celebrate their 26th birthday, we reveal the best-performing funds and investment trusts since stocks and shares ISAs launched in April 1999, and how much they would be worth today
-
Dividends: Reliability in uncertain timesDividends have formed over half of the total return of the UK market over the last 20 years. Dividend strategies have been under-appreciated while investors have focused on US mega cap technology. Income strategies may have more appeal in a tougher investment climate
